Akari Therapeutics, Plc Stock price

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.865 USD +0.27% Intraday chart for Akari Therapeutics, Plc -1.83% -40.22%
Sales 2021 - Sales 2022 - Capitalization 34.98M
Net income 2021 -17M Net income 2022 -17M EV / Sales 2021 -
Net cash position 2021 9.36M Net cash position 2022 13.25M EV / Sales 2022 -
P/E ratio 2021
-3.69 x
P/E ratio 2022
-1.65 x
Employees 15
Yield 2021 *
-
Yield 2022
-
Free-Float 51.16%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Akari Therapeutics, Plc announced that it expects to receive $1.615 million in funding CI
Akari Therapeutics, Peak Bio to Merge as Equals MT
Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading MT
More news

Latest transcript on Akari Therapeutics, Plc

1 day+0.27%
1 week-1.83%
Current month-20.64%
1 month-18.56%
3 months-40.61%
6 months-53.95%
Current year-40.22%
More quotes
1 week
1.70
Extreme 1.7001
1.90
1 month
1.66
Extreme 1.66
2.44
Current year
1.66
Extreme 1.66
3.30
1 year
1.66
Extreme 1.66
5.50
3 years
1.66
Extreme 1.66
64.00
5 years
1.66
Extreme 1.66
100.80
10 years
1.66
Extreme 1.66
522.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 22-03-27
Founder 79 15-08-31
Director of Finance/CFO 56 23-07-18
Members of the board TitleAgeSince
Director/Board Member 65 16-05-31
Founder 79 15-08-31
Director/Board Member 61 23-07-04
More insiders
Date Price Change Volume
24-03-28 1.865 +0.27% 13 382
24-03-27 1.86 -1.33% 34,771
24-03-26 1.885 -0.78% 13,901
24-03-25 1.9 +4.97% 2,448
24-03-22 1.81 -1.09% 59,394

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Akari Therapeutics, Plc is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the United States Food and Drug Administration (FDA) for nomacopan for the treatment of pediatric HSCT-TMA. Additionally, the Company has a pre-clinical program developing long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
More about the company
  1. Stock
  2. Equities
  3. Stock Akari Therapeutics, Plc - Nasdaq